Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort

Kidney International

Volumn 77, Issue 1, 2010, Pages 29-36

  Meijer, Esther ^a   Bakker, Stephan J L ^a   Halbesma, Nynke ^b   De Jong, Paul E ^a   Struck, Joachim ^c   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BRAHMS AG   (Germany)

Author keywords

Microalbuminuria; Vasopressin

Indexed keywords

ALBUMIN; COPEPTIN; UNCLASSIFIED DRUG; VASOPRESSIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HYPOTHESIS; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NEPHELOMETRY; OBSERVATIONAL STUDY; OSMOLALITY; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; URINE VOLUME;

ADULT; AGE FACTORS; ALBUMINS; ALBUMINURIA; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS; VASOPRESSINS;

EID: 72949095441     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.397     Document Type: Article

References (31)

1. Arnlov J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-975.
2. Verhave JC, Gansevoort RT, Hillege HL et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; 92: S18-S21.
3. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
4. de Zeeuw D, Remuzzi G, Parving HH. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927. (Pubitemid 39128617)
5. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001; 51: 372-390.
6. Bardoux P, Bichet DG, Martin H et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497-506.
7. Fernandes S, Bruneval P, Hagege A et al. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology 2002; 143: 2759-2766.
8. Bouby N, Bachmann S, Bichet D et al. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258: F973-F979.
9. Sugiura T, Yamauchi A, Kitamura H et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int 1999; 55: 1800-1810.
10. Bardoux P, Bruneval P, Heudes D et al. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755-1763.
11. Preibisz JJ, Sealey JE, Laragh JH et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: I129-I138.
12. Morgenthaler NG, Struck J, Alonso C et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119.
13. Morgenthaler NG, Struck J, Jochberger S et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43-49.
14. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 1999; 65: 991-1004.
15. Okada H, Suzuki H, Kanno Y et al. Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Clin Sci (Lond) 1994; 86: 399-404.
16. Cowley Jr AW, Skelton MM, Kurth TM. Effects of long-term vasopressin receptor stimulation on medullary blood flow and arterial pressure. Am J Physiol 1998; 275: R1420-R1424.
17. Sauter D, Fernandes S, Goncalves-Mendes N et al. Long-term effects of vasopressin on the subcellular localization of ENaC in the renal collecting system. Kidney Int 2006; 69: 1024-1032.
18. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001; 51: 372-390.
19. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976; 57: 1109-1116.
20. Perucca J, Bouby N, Valeix P, Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 2007; 292: R700-R705.
21. Raman A, Schoeller DA, Subar AF et al. Water turnover in 458 American adults 40-79yr of age. Am J Physiol Renal Physiol 2004; 286: F394-F401.
22. Zerbe RL, Miller JZ, Robertson GL. The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects. J Lab Clin Med 1991; 117: 51-59.
23. Lambers Heerspink HJ, Brantsma AH, De Zeeuw D et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008; 168: 897-905.
24. Mahmoodi BK, Gansevoort RT, Veeger NJ et al. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301: 1790-1797.
25. Fenske W, Stork S, Blechschmidt A et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94: 123-129.
26. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation 2003; 108: 1263-1277.
27. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470.
28. Rose BD. Clinical Physiology of Acid-Base and Electrolyte Disorders. McGraw-Hill Book Company: New York, 2001.
29. Kirschbaum B, Sica D, Anderson FP. Urine electrolytes and the urine anion and osmolar gaps. J Lab Clin Med 1999; 133: 597-604.
30. Brantsma AH, Atthobari J, Bakker SJ et al. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol 2007; 18: 637-645.
31. David SM, George P. McCabe. Introduction to the Practice of Statistics. 19-7-2002 WH Freeman: New York, USA.